Kayne Anderson Rudnick Investment Management LLC Has $43,000 Stock Holdings in Natera, Inc. $NTRA

Kayne Anderson Rudnick Investment Management LLC trimmed its stake in shares of Natera, Inc. (NASDAQ:NTRA) by 50.0% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 302 shares of the medical research company’s stock after selling 302 shares during the quarter. Kayne Anderson Rudnick Investment Management LLC’s holdings in Natera were worth $43,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. boosted its stake in shares of Natera by 0.6% in the 1st quarter. Vanguard Group Inc. now owns 12,393,827 shares of the medical research company’s stock valued at $1,752,611,000 after purchasing an additional 77,357 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Natera by 56.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 10,537,743 shares of the medical research company’s stock valued at $1,490,144,000 after purchasing an additional 3,795,315 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in Natera by 9.9% during the first quarter. JPMorgan Chase & Co. now owns 7,361,963 shares of the medical research company’s stock worth $1,041,055,000 after buying an additional 660,538 shares during the last quarter. Invesco Ltd. increased its holdings in Natera by 13.7% during the first quarter. Invesco Ltd. now owns 2,035,979 shares of the medical research company’s stock worth $287,908,000 after buying an additional 245,719 shares during the last quarter. Finally, Lord Abbett & CO. LLC boosted its position in Natera by 5.6% during the first quarter. Lord Abbett & CO. LLC now owns 1,521,300 shares of the medical research company’s stock worth $215,127,000 after purchasing an additional 80,865 shares during the period. 99.90% of the stock is owned by institutional investors.

Natera Trading Down 1.6%

Shares of NTRA opened at $163.04 on Thursday. The firm has a fifty day moving average price of $154.54 and a 200-day moving average price of $154.08. The firm has a market capitalization of $22.38 billion, a P/E ratio of -85.36 and a beta of 1.76. Natera, Inc. has a 12-month low of $110.57 and a 12-month high of $183.00.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Thursday, August 7th. The medical research company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.14). The firm had revenue of $546.60 million during the quarter, compared to the consensus estimate of $476.84 million. Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The business’s revenue was up 32.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.30) earnings per share. Natera has set its FY 2025 guidance at EPS. Analysts predict that Natera, Inc. will post -1.49 earnings per share for the current year.

Wall Street Analyst Weigh In

NTRA has been the subject of several recent analyst reports. Royal Bank Of Canada boosted their price objective on shares of Natera from $251.00 to $255.00 and gave the company an “outperform” rating in a research note on Friday, August 8th. Barclays reaffirmed an “overweight” rating and issued a $210.00 price objective (up previously from $190.00) on shares of Natera in a research note on Friday, August 8th. Wall Street Zen lowered shares of Natera from a “hold” rating to a “sell” rating in a report on Saturday, May 17th. Cowen reissued a “buy” rating on shares of Natera in a research report on Friday, August 8th. Finally, UBS Group upped their price target on shares of Natera from $211.00 to $218.00 and gave the stock a “buy” rating in a research note on Friday, May 9th. One equities research analyst has rated the stock with a Strong Buy rating and seventeen have given a Buy rating to the company. According to MarketBeat.com, Natera presently has an average rating of “Buy” and a consensus price target of $193.19.

Insider Activity at Natera

In other news, CEO Steven Leonard Chapman sold 6,111 shares of the company’s stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $157.10, for a total transaction of $960,038.10. Following the transaction, the chief executive officer owned 179,071 shares in the company, valued at $28,132,054.10. This represents a 3.30% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Gail Boxer Marcus sold 4,299 shares of the company’s stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $167.36, for a total value of $719,480.64. Following the completion of the sale, the director owned 8,118 shares in the company, valued at approximately $1,358,628.48. This represents a 34.62% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 58,705 shares of company stock worth $8,743,776. 5.63% of the stock is owned by insiders.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.